The globalcancer/tumor profiling market预计尺寸将在2027年根据Polaris市场研究的一项新的研究达到2027美元的15.32亿美元。betway苹果下载那个报告“Cancer/Tumor Profiling Market Share, Size, Trends, Industry Analysis Report by Technology (Immunoassay, NGS, PCR, In Situ Hybridization, Microarray, Mass Spectrometry, Others); By Cancer Type (Breast, Lung, Colorectal, Prostate, Melanoma, Others); By Biomarker Type (Genomic Biomarkers, Protein Biomarkers, Others); By Application (Personalized Medicine, Diagnostics, Prognostics, Biomarker Discovery, Research); By Regions – Segment – Forecast, 2020 – 2027”gives a detailed insight into current market dynamics and provides analysis on future market growth.
Increasing demand for tumor profiling and diagnosis and therapy techniques is driven by oncologists. Increased use of biomarkers in tumor profiling and increasing use of next-generation cancer profiling sequencing methods are some of the main factors driving the growth of the tumor profiling market. Tumor profiling is used to evaluate the metabolism, properties, and mutations of the tumor that can assist discover effective therapies. Drugs that target these mutated kinases can be discovered and developed based on genetic modification. The profiling is considered a requirement to increase the sensitivity of kinases-focused medications because they rely on individual tumors genetic composition. Thus, these mutated profiles of DNA tumors help to create specific anticarcinogenic treatments.
在全球范围内每年都有癌症患者崛起。根据世卫组织该疾病被认为是2019年第二年的第二个主要原因。据估计，6例死亡中有1个是由于癌症。谁标志着这种疾病的三分之一的死亡是由于5个主要的行为和饮食风险。这些因素包括高体重指数，低水果和蔬菜摄入，缺乏身体活动，烟草使用和酒精使用。烟草是癌症和死亡率普遍上升的主要因素之一，大约22％。根据谁，在2015年，约有1760万案与癌症有关，2018年增加到1810万个案件，近960万吨。患者数量上升是全球癌症/肿瘤分析市场增长的主要因素。
已经确定了认证技术，可以减少识别肿瘤和前进阶段的时间以及改善癌症研究的阶段。此外，各国各国主要生物技术公司为开发新疗法和新技术的重大投资正在全国范围内得到见证。这具有显着推动的市场增长，预计预测期间会持有增长。通过快速发展基因分析技术和个性化靶向疗法，生物标志物在癌症患者的药物制度设计方面发挥了重要作用。目前，基因组的预后生物标志物可用于预后在临床阶段进行多种癌症。然而，研究人员争辩说转换困难正在阻碍生物标志物发现的阶段与其临床转化之间的广泛分歧。肿瘤基因组数据的采集被视为癌症预测，诊断和治疗中最重要的一步。
有问题吗？在通过单击下面的链接，请在购买此报告之前请求示例或进行查询：https://www.polarismarketreesearch.com/industry-analysis/cancer-tumor-profiming-market/request-for-sample.
Next Generation Sequencing (NGS) is a sophisticated technique for the sequence that can be used for accurate tumor DNA genomic sequencing. The interpreted data contribute much more quickly to the assessment of tumor purity and the magnitude of disease progression. The primary benefit of NGS is the complete exotic sequence which helps examine all protein-coding areas of the human genome. It also enables whole genome sequencing to be useful for analysis of protein coding and non-coding areas in the human genome. Such advances in technology are one of the primary drivers of global cancer/tumor profiling market.
Moreover, the growing demand for personalized medicine further provides substantial opportunities for the tumor profiling market. The personalized medicine is defined as typical care in the treatment that is customized as per an individual patient. There have been several types of research going on presently to develop personal medicine based on the patients. Several factors should be considered before providing personal medicine to a patient. Firstly, the doctors have to detect the type or the symptoms of cancer that can be developed in a patient. Detection is important for the surgeon or the doctor, to find the best suited therapy that can treat the person. For developing a personalized medicine tumor profiling need to be taken into account as these tests will eventually reveal the various conditions of the patients such as detection of the individual developing a specific type of disease.
betway苹果下载Polaris市场研究在基础上分段了癌症肿瘤/分析市场：
癌症肿瘤/分析技术前景（收入，百万，2016 - 2027）
- Immunoassay
- NGS
- PCR
- In Situ Hybridization
- Microarray
- 质谱
- 其他
癌症肿瘤/仿形癌型前景（收入，十亿美元，2016 - 2027）
- 胸部
- Lung
- 结直肠
- 前列腺
- 黑色瘤
- 其他
Cancer Tumor/Profiling Biomarker Type Outlook (Revenue, USD Billion, 2016 – 2027)
- Genomic Biomarkers
- Protein Biomarkers
- 其他
癌症肿瘤/分析应用前景（收入，十亿美元，2016 - 2027）
- 个性化的药物
- 诊断
- 预后学
- 生物标志物发现
- 研究
Cancer Tumor/Profiling Regional Outlook (Revenue, USD Million, 2016 – 2027)
- 北美
- 我们。
- Canada
- Europe
- 英国
- Germany
- France
- Italy
- Spain
- 荷兰
- 亚太地区
- India
- 日本
- 中国
- 韩国
- 拉美
- Brazil
- 墨西哥
- 哥伦比亚
- 中东和非洲
- Saudi Arabia
- 南非
- Israel
- 阿联酋